A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2016
At a glance
- Drugs SER 100 (Primary)
- Indications Isolated systolic hypertension
- Focus Adverse reactions
- Sponsors Serodus
- 01 Jan 2016 Results analysing safety, tolerability and efficacy published in the Clinical Pharmacology in Drug Development.
- 09 Sep 2014 Results published in the Media Release.
- 09 Sep 2014 Status changed from active, no longer recruiting to completed, as reported in a Serodus media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History